We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.385 | 2.21 | 2.39 | 21,468 | 08:53:06 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.81M | -0.0114 | -2.09 | 7.93M |
From Apr 2022 to Apr 2024
By Kyle Morris
Shares in ImmuPharma PLC jumped 16% on Wednesday after the company said that it has received Food and Drug Administration confirmation for a pre-investigational new drug meeting on May 16 to consider a Phase 2/3 adaptive trial study protocol for its late-stage P140 clinical program in patients with chronic idiopathic demyelinating polyneuropathy.
The company said that a new investigational new drug submission is required as this will be the first time that P140 is to be studied in humans for the indication of CIDP.
Shares at 0716 GMT were up 0.35 pence at 2.50 pence.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
April 12, 2023 03:47 ET (07:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
